Market Place
Sourcing Support
Zevra Therapeutic Announces US Commercial Availability of Miplyffa
21 Nov 2024 //
GLOBENEWSWIRE
Orsini Named Exclusive Specialty Pharmacy for MIPLYFFA™ in U.S.
24 Sep 2024 //
PR NEWSWIRE
FDA Approves First Treatment for Niemann-Pick Disease, Type C
23 Sep 2024 //
PRNEWSWIRE
Amicus At BofA 2024 Healthcare Conference
08 May 2024 //
GLOBENEWSWIRE
Zevra: Arimoclomol Long-Term NPC Safety, Efficacy At SIMD
15 Apr 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol
04 Mar 2024 //
GLOBENEWSWIRE
Zevra Receives FDA Acceptance of Resubmission of NDA for Arimoclomol
08 Jan 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Announces Resubmission of Arimoclomol NDA to FDA
27 Dec 2023 //
GLOBENEWSWIRE
Zevra Announces Arimoclomol Research Featured in Poster Presentations
24 Feb 2023 //
GLOBENEWSWIRE
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
17 May 2022 //
BUSINESSWIRE
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme
15 May 2022 //
GLOBENEWSWIRE
Orphazyme announces withdrawal of EMA Application for arimoclomol
22 Mar 2022 //
GLOBENEWSWIRE
Orphazyme to assess strategic options after EU advisers nix drug
25 Feb 2022 //
BIOSPACE
CytRx Highlights Orphazyme`s Update on Planned NDA Resubmission for Arimoclomol
14 Feb 2022 //
BUSINESSWIRE
Orphazyme to present additional data on arimoclomol’s MOA
07 Feb 2022 //
GLOBENEWSWIRE
Orphazyme announces regulatory update for arimoclomol
06 Oct 2021 //
PHARMABIZ
CytRx Highlights Orphazyme’s Results From Its Phase 2/3 Trial of Arimoclomol
24 Aug 2021 //
BUSINESSWIRE
Orphazyme announces update on for arimoclomol
28 Jun 2021 //
GLOBENEWSWIRE
Orphazyme presents 36-month data supporting durable response to arimoclomol
28 Jun 2021 //
GLOBENEWSWIRE
CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol
01 Jan 2021 //
BUSINESSWIRE
ORPHAZYME PROVIDES REGULATORY UPDATE ON ARIMOCLOMOL FOR NPC
28 Dec 2020 //
ORPHAZYME
ORPHAZYME PROVIDES REGULATORY UPDATE ON ARIMOCLOMOL FOR NPC
28 Dec 2020 //
ORPHAZYME
CytRx Highlights Orphazyme’s Acceleration of Pre-Launch for Arimoclomol
27 Oct 2020 //
BUSINESSWIRE
ORPHAZYME ACCELERATES ARIMOCLOMOL PRE-LAUNCH ACTIVITIES AND UPDATES
23 Oct 2020 //
PRESS RELEASE
CytRx Highlights Orphazyme’s Receipt of FDA Acceptance
17 Sep 2020 //
BIOSPACE
Orphazyme gets speedy look at the FDA
15 Sep 2020 //
ENDPOINTS
CytRx Corporation Highlights Significant Positive Events
19 Dec 2019 //
PR NEWSWIRE
Orphazyme to prepare for filing of arimoclomol in US
22 Jul 2019 //
GLOBE NEWSWIRE
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in ALS
17 Jul 2019 //
GLOBE NEWSWIRE
Orphazyme to Prepare MAA Submission in Europe for Niemann-Pick Disease Type C
20 Jun 2019 //
PR NEWSWIRE
Orphazyme announces positive results from phase 2/3 trial of arimoclomol
08 Feb 2019 //
PHARMA BIZ
Orphazyme plans to pitch subgroup analyses of key study to regulators
31 Jan 2019 //
ENDPTS
